Minor H antigen-specific CTL lines generated by primary in vitro stimulation for 10 recipient donor pairs
| ID . | Sex, (patient/donor) . | Age, y (patient/donor) . | Class I HLA antigens (patient and donor) . | Patient diagnosis . | CD8+ TN cells stimulated . | No. of CTL lines with cytotoxicity greater than 20% (ET 10:1) . |
|---|---|---|---|---|---|---|
| 1 | Female/female | 18/22 | A1, A2 | AML | 13 × 106 | 13 |
| B8, B55 | ||||||
| C7, C3 | ||||||
| 2 | Male/female | 43/39 | A2, A2 | RAEB | 20 × 106 | 14 |
| B38, B40 | ||||||
| C7, C7 | ||||||
| 3 | Male/male | 40/45 | A1, A2 | T-ALL | 16.8 × 106 | 6 |
| B8, B18 | ||||||
| C7, C7 | ||||||
| 4 | Male/male | 52/58 | A2, A2 | PLL | 20 × 106 | 2 |
| B7, B7 | ||||||
| C7, C7 | ||||||
| 5 | Male/female | 47/45 | A24, A32 | AML | 31.5 × 106 | 11 |
| B35, B44 | ||||||
| C4,C4 | ||||||
| 6 | Female/male | 51/52 | A1, A3 | B-ALL | 31 × 106 | 5 |
| B8, B49 | ||||||
| C7, C7 | ||||||
| 7 | Male/female | 23/25 | A1, A68 | AML | 50 × 106 | 24 |
| B44, B55 | ||||||
| C5,C3 | ||||||
| 8 | Male/female | 30/32 | A2, A3 | Hodgkin disease | 18 × 106 | 4 |
| B7, B18 | ||||||
| C7, C7 | ||||||
| 9 | Male/male | 53/48 | A1, A2 | AML | 30 × 106 | 41 |
| B8, B14 | ||||||
| C7, C8 | ||||||
| 10 | Female/female | 42/50 | A1, A2 | RA | 22 × 106 | 20 |
| B7, B27 | ||||||
| C7, C2 |
| ID . | Sex, (patient/donor) . | Age, y (patient/donor) . | Class I HLA antigens (patient and donor) . | Patient diagnosis . | CD8+ TN cells stimulated . | No. of CTL lines with cytotoxicity greater than 20% (ET 10:1) . |
|---|---|---|---|---|---|---|
| 1 | Female/female | 18/22 | A1, A2 | AML | 13 × 106 | 13 |
| B8, B55 | ||||||
| C7, C3 | ||||||
| 2 | Male/female | 43/39 | A2, A2 | RAEB | 20 × 106 | 14 |
| B38, B40 | ||||||
| C7, C7 | ||||||
| 3 | Male/male | 40/45 | A1, A2 | T-ALL | 16.8 × 106 | 6 |
| B8, B18 | ||||||
| C7, C7 | ||||||
| 4 | Male/male | 52/58 | A2, A2 | PLL | 20 × 106 | 2 |
| B7, B7 | ||||||
| C7, C7 | ||||||
| 5 | Male/female | 47/45 | A24, A32 | AML | 31.5 × 106 | 11 |
| B35, B44 | ||||||
| C4,C4 | ||||||
| 6 | Female/male | 51/52 | A1, A3 | B-ALL | 31 × 106 | 5 |
| B8, B49 | ||||||
| C7, C7 | ||||||
| 7 | Male/female | 23/25 | A1, A68 | AML | 50 × 106 | 24 |
| B44, B55 | ||||||
| C5,C3 | ||||||
| 8 | Male/female | 30/32 | A2, A3 | Hodgkin disease | 18 × 106 | 4 |
| B7, B18 | ||||||
| C7, C7 | ||||||
| 9 | Male/male | 53/48 | A1, A2 | AML | 30 × 106 | 41 |
| B8, B14 | ||||||
| C7, C8 | ||||||
| 10 | Female/female | 42/50 | A1, A2 | RA | 22 × 106 | 20 |
| B7, B27 | ||||||
| C7, C2 |
CTL indicates cytotoxic T lymphocyte; RAEB indicates refractory anemia with excess blasts; T-ALL, T-cell acute lymphoblastic leukemia; PLL, prolymphocytic leukemia; B-ALL, B-cell acute lymphoblastic leukemia; and RA, refractory anemia.